WO2002030471A3 - A novel system for the evaluation of the activity and/or specificity of a viral component - Google Patents

A novel system for the evaluation of the activity and/or specificity of a viral component Download PDF

Info

Publication number
WO2002030471A3
WO2002030471A3 PCT/EP2001/011626 EP0111626W WO0230471A3 WO 2002030471 A3 WO2002030471 A3 WO 2002030471A3 EP 0111626 W EP0111626 W EP 0111626W WO 0230471 A3 WO0230471 A3 WO 0230471A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral
animal
present
transgenic
specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/011626
Other languages
French (fr)
Other versions
WO2002030471A2 (en
Inventor
Matthias Renner
Walter Guenzburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Austrian Nordic Biotherapeutics AG
Bavarian Nordic GmbH
Original Assignee
Austrian Nordic Biotherapeutics AG
Bavarian Nordic GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austrian Nordic Biotherapeutics AG, Bavarian Nordic GmbH filed Critical Austrian Nordic Biotherapeutics AG
Priority to EP01986610A priority Critical patent/EP1341558A2/en
Priority to CA002425293A priority patent/CA2425293A1/en
Priority to AU2002218218A priority patent/AU2002218218A1/en
Priority to JP2002533910A priority patent/JP2004535151A/en
Publication of WO2002030471A2 publication Critical patent/WO2002030471A2/en
Publication of WO2002030471A3 publication Critical patent/WO2002030471A3/en
Priority to US10/410,469 priority patent/US20030229903A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method for the evaluation of the activity and/or specificity of a regulatory sequence or of a viral component, wherein a viral vector is introduced into a cell of a transgenic non-human animal comprising in its genome one or more viral sequences. However, said transgenic animal is deficient in at least one viral sequence required for generation of the virus. This viral sequence is included in the viral vector introduced into the cell of the transgenic animal, thereby allowing reconstitution of viral particle generation in the transgenic animal. After maintaining the transgenic animal under suitable conditions allowing the production of viral particles, the cells in which viral particles are produced can be detected and evaluated, respectively. The method according to the present invention can also be adapted to evaluate the distribution of a receptor for a ligand in an animal. The present invention also provides a transgenic non-human animal applicable for use in the method according to the present invention.
PCT/EP2001/011626 2000-10-10 2001-10-08 A novel system for the evaluation of the activity and/or specificity of a viral component Ceased WO2002030471A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01986610A EP1341558A2 (en) 2000-10-10 2001-10-08 A novel system for the evaluation of the activity and/or specificity of a viral component
CA002425293A CA2425293A1 (en) 2000-10-10 2001-10-08 A novel system for the evaluation of the activity and/or specificity of a viral component
AU2002218218A AU2002218218A1 (en) 2000-10-10 2001-10-08 A novel system for the evaluation of the activity and/or specificity of a viral component
JP2002533910A JP2004535151A (en) 2000-10-10 2001-10-08 New system for evaluation of activity and / or specificity of viral components
US10/410,469 US20030229903A1 (en) 2000-10-10 2003-04-09 Novel system for the evaluation of the activity and/or specificity of a viral component

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001519 2000-10-10
DKPA200001519 2000-10-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/410,469 Continuation US20030229903A1 (en) 2000-10-10 2003-04-09 Novel system for the evaluation of the activity and/or specificity of a viral component

Publications (2)

Publication Number Publication Date
WO2002030471A2 WO2002030471A2 (en) 2002-04-18
WO2002030471A3 true WO2002030471A3 (en) 2003-02-27

Family

ID=8159785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/011626 Ceased WO2002030471A2 (en) 2000-10-10 2001-10-08 A novel system for the evaluation of the activity and/or specificity of a viral component

Country Status (6)

Country Link
US (1) US20030229903A1 (en)
EP (1) EP1341558A2 (en)
JP (1) JP2004535151A (en)
AU (1) AU2002218218A1 (en)
CA (1) CA2425293A1 (en)
WO (1) WO2002030471A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103374085B (en) 2012-04-26 2016-04-27 中国石油化工股份有限公司 A kind of Mannich base, its manufacture method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002805A2 (en) * 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
WO1995003399A2 (en) * 1993-07-19 1995-02-02 Cantab Pharmaceuticals Research Limited Production method for preparation of disabled viruses
WO1997038118A1 (en) * 1996-04-05 1997-10-16 Universite Pierre Et Marie Curie (Paris Vi) Defective viral vaccine particles obtained in vivo or ex vivo
WO1998044788A2 (en) * 1997-04-09 1998-10-15 Chang Lung Ji Animal model for evaluation of vaccines
WO1999020742A2 (en) * 1997-10-20 1999-04-29 Universita' Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
WO1999035280A1 (en) * 1998-01-06 1999-07-15 Bavarian Nordic Research Institute A/S Reconstituting retroviral vector (recon vector) for targeted gene expression
US5948675A (en) * 1994-02-22 1999-09-07 Universite Pierre Et Marie Curie (Paris Vi) Host-vector system which can be used in gene therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US6248721B1 (en) * 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002805A2 (en) * 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
WO1995003399A2 (en) * 1993-07-19 1995-02-02 Cantab Pharmaceuticals Research Limited Production method for preparation of disabled viruses
US5948675A (en) * 1994-02-22 1999-09-07 Universite Pierre Et Marie Curie (Paris Vi) Host-vector system which can be used in gene therapy
WO1997038118A1 (en) * 1996-04-05 1997-10-16 Universite Pierre Et Marie Curie (Paris Vi) Defective viral vaccine particles obtained in vivo or ex vivo
WO1998044788A2 (en) * 1997-04-09 1998-10-15 Chang Lung Ji Animal model for evaluation of vaccines
WO1999020742A2 (en) * 1997-10-20 1999-04-29 Universita' Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
WO1999035280A1 (en) * 1998-01-06 1999-07-15 Bavarian Nordic Research Institute A/S Reconstituting retroviral vector (recon vector) for targeted gene expression

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DONG J ET AL: "ANALYSIS OF RETROVIRAL ASSEMBLY USING A VACCINIA/T7-POLYMERASE COMPLEMENTATION SYSTEM", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 194, no. 1, 1 May 1993 (1993-05-01), pages 192 - 199, XP000608725, ISSN: 0042-6822 *
JENKINS S ET AL: "FORMATION OF LENTIVIRUS PARTICLES BY MAMMALIAN CELLS INFECTED WITH RECOMBINANT FOWLPOX VIRUS", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 7, no. 12, 1 December 1991 (1991-12-01), pages 991 - 998, XP000607853, ISSN: 0889-2229 *
LEDLEY F D: "HEPATIC GENE THERAPY: PRESENT AND FUTURE", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 18, November 1993 (1993-11-01), pages 1263 - 1273, XP002905069, ISSN: 0270-9139 *
MEHTALI MAJID ET AL: "A novel transgenic mouse model for the in vivo evaluation of anti-human immunodeficiency virus type 1 drugs.", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 8, no. 12, 1992, pages 1959 - 1966, XP001095446, ISSN: 0889-2229 *
MOLDOVEANU Z ET AL: "IMMUNE RESPONSES INDUCED BY ADMINISTRATION OF ENCAPSIDATED POLIOVIRUS REPLICONS WHICH EXPRESS HIV-1 GAG AND ENVELOPE PROTEINS", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 13, no. 11, 1 August 1995 (1995-08-01), pages 1013 - 1022, XP000571592, ISSN: 0264-410X *

Also Published As

Publication number Publication date
WO2002030471A2 (en) 2002-04-18
EP1341558A2 (en) 2003-09-10
US20030229903A1 (en) 2003-12-11
CA2425293A1 (en) 2002-04-18
JP2004535151A (en) 2004-11-25
AU2002218218A1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
Kutscher et al. Forward and reverse mutagenesis in C. elegans
Chalker et al. Non-Mendelian, heritable blocks to DNA rearrangement are induced by loading the somatic nucleus of Tetrahymena thermophila with germ line-limited DNA
JP6888213B2 (en) Simple and highly efficient method for producing genetically modified non-human mammals
Kranz et al. An improved Flp deleter mouse in C57Bl/6 based on Flpo recombinase
Jaenisch et al. Infection of preimplantation mouse embryos and of newborn mice with leukemia virus: tissue distribution of viral DNA and RNA and leukemogenesis in the adult animal.
WO2005079462A3 (en) Methods and materials using signaling probes
AU5587001A (en) Databases of regulatory sequences; methods of making and using same
JP2002535994A5 (en)
JP2016165307A5 (en)
JP2016504026A5 (en)
FI950277A0 (en) Production of xenogenic antidotes
MX2022010835A (en) Rna-guided genome recombineering at kilobase scale.
WO2003080816A3 (en) Stem cell culture
WO2017080452A1 (en) Parthenogenetic haploid embryonic stem cells, preparation method therefor, and application thereof
TR200200693T2 (en) Herbal regulatory sequences for control of gene expression
Tian et al. Macrocrack–microcrack interaction problem in magnetoelectroelastic solids
JP2003502064A5 (en)
WO2002030471A3 (en) A novel system for the evaluation of the activity and/or specificity of a viral component
Singh et al. CRISPR/Cas9 guided genome and epigenome engineering and its therapeutic applications in immune mediated diseases
TR200001046T2 (en) Positive and negative selection in homologous recombination.
CA2271785A1 (en) Methods for preparing nucleotide integrases
Bataille et al. Equimolar generation of the four possible arrangements of adjacent L components in herpes simplex virus type 1 replicative intermediates
WO2005017127A3 (en) Rna interference compositions and methods
AU2400202A (en) Promoters exhibiting endothelial cell specificity and methods of using same
EP0859059A3 (en) Methods and materials for introducing exogenous genes into cultured cells or fertilized eggs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001986610

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2425293

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10410469

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002533910

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001986610

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001986610

Country of ref document: EP